WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Dr. Adil Rifaie Hannawi*, Dr. Mujahed Hashim Taha, Dr. Omar Samir Yahya, Dr. Shahir Khalaf Ahmed

ABSTRACT

Background: Diabetic macular edema (DME) is a major cause of visual impairment in diabetic patients. Treatment modalities include intravitreal triamcinolone acetonide, pars plana vitrectomy, and antivascular endothelial growth factor (VEGF) therapy. Intravitreal anti-VEGF agents have revolutionized DME treatment, with some studies suggesting better visual acuity compared to posterior sub-Tenon injection (STB). Aim of the study: To evaluate the effectiveness of sub-Tenon injections of bevacizumab for the treatment of macular edema. Patients and Methods: A non-comparative, prospective interventional case series included 47 patients with diabetic macular edema that was clinically substantial were joined. Monthly macular photocoagulation was carried after following STB injections. history of intraocular surgery, retinal laser photocoagulation, high refractive errors, media opacity, glaucoma, ischemic optic neuropathy, uveitis, retinal vascular occlusion, diseases of the vitreomacular interface, and panretinal photocoagulation were among the exclusion criteria. Version 26 of SPSS was used to compile and analyze the data. Results: The experimental analysis included 47 patients, with a mean age of 57.62 years and 61.7%) being males. The mean OCT scores before treatment were 328.34 μm. Only 12.8% had both eyes affected, and there was no significant increase in OCT results after treatment. The McNemar Bowker test was insignificant for the Best Corrected Visual Acuity test. Conclusion: The current study concluded that the sub-tenon injection of the Bevacizumab had no role in treatment of DME.